CA Patent

CA3201612A1 — Combination therapies for the treatment of cancer

Assigned to Erasca Inc · Expires 2022-06-16 · 4y expired

What this patent protects

The present disclosure provides methods of treating cancer with combination therapies of a SHP2 inhibitor and a KRAS G12C inhibitor.

USPTO Abstract

The present disclosure provides methods of treating cancer with combination therapies of a SHP2 inhibitor and a KRAS G12C inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
CA3201612A1
Jurisdiction
CA
Classification
—
Expires
2022-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Erasca Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.